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ORIGINAL ARTICLE

Extracellular vesicle RNAs reflect placenta dysfunction and
are a biomarker source for preterm labour
Shannon Fallen1

| David Baxter1 | Xiaogang Wu1 | Taek-Kyun Kim1 |

Oksana Shynlova2,3,4

| Min Young Lee1 | Kelsey Scherler1 | Stephen Lye2,3,4 |

Leroy Hood1 | Kai Wang1
1

Institute for Systems Biology, Seattle, WA,
USA
2

Lunenfeld-Tanenbaum Research Institute,
Mount Sinai Hospital, Toronto, ON, Canada
3

Department of Obstetrics & Gynecology,
University of Toronto, Toronto, ON,
Canada
4

Department of Physiology, University of
Toronto, Toronto, ON, Canada

Abstract
Preterm birth (PTB) can lead to lifelong complications and challenges. Identifying
and monitoring molecular signals in easily accessible biological samples that can
diagnose or predict the risk of preterm labour (PTL) in pregnant women will reduce
or prevent PTBs. A number of studies identified putative biomarkers for PTL including protein, miRNA and hormones from various body fluids. However, biomarkers
identified from these studies usually lack consistency and reproducibility. Extracellu-
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lar vesicles (EVs) in circulation have gained significant interest in recent years as
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sion chromatography (SEC)-based EV purification method to gain a comprehensive

these vesicles may be involved in cell-cell communication. We have used an
improved small RNA library construction protocol and a newly developed size excluview of circulating RNA in plasma and its distribution by analysing RNAs in whole
plasma and EV-associated and EV-depleted plasma. We identified a number of miRNAs in EVs that can be used as biomarkers for PTL, and these miRNAs may reflect
the pathological changes of the placenta during the development of PTL. To our
knowledge, this is the first study to report a comprehensive picture of circulating
RNA, including RNA in whole plasma, EV and EV-depleted plasma, in PTL and reveal
the usefulness of EV-associated RNAs in disease diagnosis.
KEYWORDS

exosome, extracellular vesicle, microRNA, next-generation sequencing, preterm birth, preterm
labour

1 | INTRODUCTION

illnesses that extend into adulthood.1 This increased lifelong morbidity results in high economic and social costs to families and commu-

Preterm birth (PTB) is childbirth occurring at <37 completed weeks

nities.1,2 Identifying and monitoring molecular signals in easily

of gestation.1 PTB is the second largest direct cause of death in chil-

accessible body fluids that can diagnose or predict the risk of pre-

dren younger than 5 years, and complications associated with PTB

term labour (PTL) in pregnant women will reduce or prevent PTBs.

are estimated to be responsible for 35% of the world’s 3.1 million

Protein has been the major player of diagnostic markers used in

annual neonatal deaths.2 Premature babies have higher rates of cere-

the clinic. For example, prostate-specific antigen (PSA) is measured

bral palsy, sensory deficits, learning disabilities and respiratory

for prostate cancer progression3 and alpha foetal protein for liver-
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related conditions.4 In recent years, cell-free circulating nucleic acids,

encapsulated in EVs, as a non-invasive biomarker for PTL. To our

especially circulating microRNA (miRNA), have garnered much atten-

knowledge, this is the first comprehensive characterization of circu-

tion for their potential as a disease biomarker. MiRNAs are evolu-

lating RNA encompassing whole plasma, EV and EV-depleted plasma

tionary conserved, small non-coding RNAs ranging in size from 19 to

in PTL.

24 nucleotides. They regulate various biological activities by modulating the cellular transcriptome and proteome.5,6 Besides their regulatory roles in the cell, miRNAs can also be detected in various body
fluids. These cell-free circulating miRNAs are either bound to RNAbinding proteins, such as NPM1 or Ago2,7 or lipoproteins, such as

2 | MATERIALS AND METHODS
2.1 | Ethics statement

HDL or LDL,8 or encapsulated into extracellular vesicles (EVs) to

This study was approved by the Research Ethics Board of Mount

escape RNase degradation.6,9 Some circulating miRNAs are already

Sinai Hospital, Toronto, Canada (#04-0024-E), and was conducted

used as markers for disease diagnosis or prognosis. For example, the

according to the principles of Declaration of Helsinki. All patients

circulating miR-122 level is closely associated with different liver dis-

provided written informed consent to participate in the Global Alli-

eases

10

and miR-208 level is associated with heart conditions.11,12

ance to Prevent Prematurity and Stillbirth (GAPPS) study.

It has been suggested that at least some of the EVs, including exosomes, are involved in cell-cell communication.13 Therefore, characterizing the molecular content and studying the function of EVs

2.2 | Patient and sample information
Blood samples were collected from women who had PTL and gesta-

have been of great interest in recent years.
A number of studies report putative biomarkers for PTL including

tional age-matched healthy pregnant women. Inclusion criteria for

protein, miRNA and hormones from various body fluids such as

the study were presentation between 24 and 34 weeks of gestation

saliva and amniotic

with uterine contractions and cervical dilation <4 cm. Women who

fluids.15 They can largely be grouped into three main categories:

had antepartum haemorrhage, clinical chorioamnionitis, foetal anom-

inflammatory-related molecules, placenta or foetal-derived molecules

aly, preeclampsia, intrauterine growth restriction, diabetes mellitus or

and stress-related molecules. For example, several inflammation-

gestational diabetes were excluded. The women formed part of the

related proteins, including C-reactive protein and cytokines, including

Ontario Birth Study cohort, at Sinai Health System, Toronto, Canada.

IL6, IL8 and IL10, show PTL-associated concentration changes.16-19

For all preterm labouring patients, peripheral blood samples were

However, biomarkers identified from these studies lack consistency,

collected prospectively at the point of hospital admission (PTL group,

especially for cell-free miRNA-based biomarkers. For example, multi-

N = 20), while blood samples from healthy control women matched

ple studies report changes of specific miRNA concentrations in

with respect to gestational age and other variables were collected

serum or plasma of PTL patients, but the results are inconsistent or

during the regular antenatal visit (TL group, N = 47). All controls

even contradictory among studies.20-24 Elovitz et al, using microar-

delivered at full term (≥37 gestational weeks).

14,15

serum and plasma,

15

cervical vaginal fluid,

ray, concluded that PTL has very little effect on serum-derived
miRNA; however, Gray et al, using the nanostring platform, identified several miRNAs that can be used to predict the development of
PTL.23,24 The major causes of inconsistency are different types of

2.3 | Sample collection, extracellular vesicle
isolation and electron microscopy

sample used (serum vs. plasma), low RNA concentration in samples

Blood samples were collected from women who participated in the

and lack of robust measurement technology. In the past few years,

GAPPS study into EDTA-treated blood collection tubes, and the

next-generation sequencing (NGS) has become the major platform

plasma was prepared according to standard protocol. Briefly, whole-

for miRNA analysis, especially for body fluid samples. Yet studies

blood samples were centrifuged for 15 minutes at 20009 g at 4°C.

have shown significant sequence bias among different small RNA

The resulting supernatant is designated plasma. The plasma was

library preparation protocols.25,26 We adapted a small RNA library

transferred to clean polypropylene tubes in 100 lL aliquots and fro-

construction protocol using adapters with 4 degenerated nucleotides

zen at 80°C. Prior to exosome isolation or RNA extraction, plasma

at miRNA-adapter ligation ends to reduce ligation-associated

was spun at 10 0009 g for 15 minutes at 4°C to remove platelets

sequence bias. In addition, ultracentrifugation has been the method

and large particles. EVs were isolated from 100 lL of plasma from a

of choice for EV purification but the high centrifugation force may

total of 22 selected samples, 11 from each group (Table S1), using

alter the natural state and content of EVs. Furthermore, the method

size exclusion chromatography (SEC) columns (iZON qEV, Cam-

is low throughput and requires large sample volume. We tested a

bridge, MA) with degassed 1X PBS (pH 7.2; Gibco, Grand Island,

newly developed size exclusion chromatography (SEC)-based EV

NY). The detailed description for EV and EV-depleted plasma prepa-

purification protocol that provides higher throughput and cleaner

ration is in Supporting information. To confirm the purification of

27,28

We are using these improved

EVs from samples, the samples were examined with transmission

approaches to gain more reliable profiles of circulating RNA in body

electron microscopy at the Fred Hutchinson Cancer Research Center

fluid as well as its associated EVs and EV-depleted plasma to explore

following the method as previously described.29 The characterization

the possibility of using circulating miRNAs, specifically those

of EV is detailed in the Supporting information.

EVs compared to other methods.
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thermocycler. Enzyme was activated at 95°C for 10 minutes followed by 40 2-step cycles of amplification at 95°C for 15 seconds

RNA was isolated from all 67 plasma samples, the 22 EV samples

and 60°C for 60 seconds. MiR-16 (hsa-miR-16-5p) was used as a

and 22 corresponding EV-depleted plasmas using miRNeasy Micro

normalization control for each assay, as miR-16-5p did not show sig-

Kit (Qiagen, Germantown, MD). The quality and quantity of the RNA

nificant concentration changes across samples.

were evaluated with the Agilent 2100 Bioanalyser (Santa Clara, CA)
and NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE).

2.8 | Functional enrichment and network analyses
The biological impacts of PTL-associated circulating miRNAs were

2.5 | Small RNA sequencing library construction

assessed using predicted and validated miRNA-mRNA interactions
from miRTar database.31,32 To focus on the possible functional

Small RNA sequencing libraries were generated using a modified

changes in placenta, we filtered the miRNA target gene list with pro-

small RNAseq protocol (available at http://exrna.org/resources/proto

tein/transcript enriched in placenta based on human protein atlas.33

cols/). Key elements of the protocol include the addition of 4 ran-

To gain a more complete view of perturbed network in PTL, we

dom nucleotides at the appropriate end of the adapters to reduce

expanded the initial miRNA-mRNA interaction with information from

ligation-associated sequence bias, the use of higher adapter concen-

protein-protein interaction databases.34-36 Functional enrichment

trations and the increased amounts of polyethylene glycol in the

analyses were conducted with DAVID (Database for Annotation,

ligation steps. In addition, to reduce the adapter-dimer, an initial size

Visualization and Integrated Discovery) webtool.37 Cytoscape and

selection is performed after 4 cycles of library amplification followed

KEGG pathway information were used to generate the network.38,39

by a second size selection after 11-16 cycles of amplification of

The process is illustrated in Figure S1.

library from the first size selection step. Individual library concentrations were measured using the NEBNext Library Quant Kit (New
England Biolabs, Ipswich, MA) and adjusted to a final pooled concentration of 2 nmol/L and sequenced using the NEXTseq DNA sequencer (Illumina, San Diego, CA).

3 | RESULTS
3.1 | Characteristics of study participants
Demographics of the 67 pregnant women (47 controls and 20 PTLs)

2.6 | RNASeq data analysis
The raw sequence data have been deposited in NCBI’s Gene Expres30

who participated in the study are presented in Table S1. Samples
from 11 preterm pregnancies and 11 matched normal pregnancies
were selected for further processing of EVs and EV-depleted plasma.

and are accessible through GEO Series accession

Among the selected samples for EV analysis, all women reported

number GSE106224 (https://www.ncbi.nlm.nih.gov/geo/query/acc.c

previous pregnancies while half of the women had previously deliv-

gi?acc=GSE106224). The results were analysed using an in-house

ered a child and none of them had a previous preterm birth. The

small RNA analysis pipeline, sRNAnalyser (available at http://srnan

mean gestational age at delivery among the 11 PTL cases was

alyzer.systemsbiology.net/), which contains three major components:

27.9 weeks and ranged between 23.3 and 33 weeks. The mean ges-

data preprocessing, sequence mapping and results summarization. In

tational age at delivery among the 11 controls was 39.9 weeks and

the data preprocessing step, the adaptor sequences were trimmed

ranged between 38.1 and 41.7 weeks. Characterization of SEC per-

and the low-quality sequences such as low nucleotide complexity

formance and EVs purified with the column is described in Support-

reads—homopolymer sequences or di- and tri-nucleotide repeat

ing information and Figure S2.

sion Omnibus

sequences were removed. The processed sequences were then
mapped against various databases including known human miRNA,
human transcripts, followed by human genomic sequence. We also
applied three different levels of error tolerance: 0 mismatch, 1 mis-

3.2 | General statistics for small RNA sequencing
results

match and 2 mismatches when aligning read sequence to databases.

For sequencing results, we obtained on average about 12 million raw

To be considered as detectable RNA species, the RNA has to have

reads in whole plasma and 8.5 million in EV-depleted plasma samples

more than 10 mapped reads in at least 70% of the samples.

(Table 1). The average read count in the EV fractions is much higher
because one control sample has more than 150 million reads. We did

2.7 | Validation of small RNASeq Results

not observe any significant difference in raw read counts between
controls and PTL samples. The number of observed and detectable

The changes of miRNA concentrations determined by NGS were val-

miRNAs is highest for plasma and lowest for EV in both the control

idated using the Taqman miRNA Assay kit. In brief, 2 ll of isolated

and PTL sets (Table 1). As expected, the overall miRNA profiles among

RNA from individual samples was reverse transcribed using the Taq-

the plasma, EV and EV-depleted fractions are similar and 10 of the top

Man microRNA RT kit (Thermo Fisher, Waltham, MA). Real-time

20 most abundant miRNAs are the same in all three sample types (Fig-

qPCR amplification was performed on the BioRad C1000 Touch

ure 1, Table S2). Among the detectable miRNAs (at least 10 mapped
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T A B L E 1 General statistics for small RNA sequencing results
Whole-plasma
control (47)

Whole-plasma
PTL (20)

EV control (11)

EV PTL (11)

EV-dep plasma
control (11)

EV-dep
plasma PTL(11)

12 900 538

11 024 622

23 129 552

9 374 019

8 509 117

8 516 263

Trimmed read count

9 479 818

8 306 794

18 135 858

7 105 360

6 581 375

6 582 738

Total miRNA mapped read

5 756 581

5 449 807

8 827 618

2 491 957

3 721 653

3 909 309

1375

1313

998

966

1188

1111

651

648

512

499

584

487

Raw read count

Number of observed miRNA
(at least one mapped read)
Detectable miRNA (10 or more
mapped reads in at
least 70% of samples)

F I G U R E 1 The overall distribution of miRNA independent of PTL (top panels) and PTL-affected miRNAs (lower panels) in whole plasma, EV
and EV-depleted plasma (indicated on the left). The concentrations of all known miRNAs are displayed according to their chromosomal location
(indicated on top). The strength of yellow colour of vertical bars represents the average concentrations observed in whole plasma, EV and EVdepleted plasma (left) used in the study. The red (increased concentration in PTL compared to controls) and green (decreased concentration in
PTL) colour bars represent the miRNA concentration changes associated with PTL. The two miRNA clusters in chromosome 14 and 19 are
boxed. Even though the overall profiles of miRNA in different sample types are similar (upper panels), there are some miRNAs showing
significant concentration differences associated with PTL. These concentration differences may be significant in one sample type (whole
plasma) yet become insignificant in another (EV) demonstrating that the mechanisms by which the placenta releases them into circulation
(either protein bound or packaged into exosomes) are differently affected by PTL
reads in 70% of samples), 481 of them are present in all three sample

to be processed into 104 mature miRNAs.40-42 95 of the mature

types (Figure S3). Interestingly, 15 unique miRNAs were detected in

miRNAs were represented by at least one mapped read across all

the EV-depleted plasma and 9 unique miRNAs were identified in EV;

sample types (whole plasma, EV and EV-depleted plasma) in our

these miRNAs may have been too dilute in the whole plasma and

analysis. The concentrations of miRNAs from the C14MC cluster

therefore below our detectable limit.

were generally decreased in the PTL group compared to normal ges-

Even though the overall profiles of miRNA in different samples

tation group (Figures 1, 2A and 3A). The only PTL-affected miRNA

are similar, there are some miRNAs showing concentration differ-

shared among all 3 sample types is hsa-miR-377-3p, a miRNA that is

ences associated with PTL (Figures 1, 2 and 3). Affected miRNAs in

known to be enriched in the placenta.

whole plasma, EV and EV-depleted plasma are listed in Table 2. It is

The chromosome 19 (C19MC) cluster is primate-specific and

interesting that a large portion of the PTL-affected RNAs in whole

consists of 50 miRNA precursors (miRBase, www.mirbase.org) that

plasma and EV are from two major miRNA clusters, one on chromo-

can produce 100 mature miRNAs and 91 of them were observed in

some 14 and the other on chromosome 19 (Figures 1, 2A, B and C).

our dataset. Our data showed that the concentrations of miRNAs

The miRNAs in these clusters have been implicated in placenta

from the C19MC cluster, like those in the C14MC cluster, were gen-

development.20

erally decreased in the PTL group compared to the normal gestation

The chromosome 14 microRNA cluster (C14MC) is located at the

group, especially in the EV fraction (Figures 1, 2B and 3B). A study

imprinted, maternally expressed DLK-DIO3 region on the human

by Morales-Prieto et al43 showed that expression of miRNAs within

chromosome 14q32 and is the largest known miRNA cluster with 52

C19MC increases significantly from the first to the third-trimester

miRNA precursors (miRBase, www.mirbase.org) having the potential

trophoblast, whereas that of C14MC members decreases.

2764
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F I G U R E 2 Circulating miRNA affected by PTL. The volcano plots show the effects of PTL on circulating miRNA in whole plasma (A), EV (B)
and EV-depleted plasma (C). The bar graph (D) and Venn diagram (E) show the number of affected miRNA in different sample types. Figures
(F) (whole plasma), (G) (EV) and H (EV-depleted plasma) are mean-centred expression profiles of affected miRNAs. The patient conditions are
indicated on top of the figures. The colours represent the miRNA concentrations that are either higher (red) or lower (green) than the average
concentration of specific miRNA across all the samples

3.3 | qPCR validation of affected miRNAs

circulating miRNAs (164 in total) whose concentrations were changed in PTL. The results feature many of the same PTL-affected miR-

Based on the RNASeq profiling results, we selected a handful of miR-

NAs in placenta or maternal plasma reported in prior studies;

NAs to be verified by qPCR: hsa-miR-127-3p and hsa-miR-181c-5p

however, the direction of concentration change is not always in

for whole plasma; hsa-miR-100-5p, hsa-miR-141-3p, hsa-miR-194-5p,

agreement.45,46 Nevertheless, this is the first comprehensive charac-

hsa-miR-515-5p, hsa-miR-517a-3p, hsa-miR518e-5p and hsa-miR-

terization of RNA in whole plasma, EV and EV-depleted plasma frac-

525-5p for EV-associated; hsa-miR-377-3p for all three sample types;

tions in PTL and provides insight into the effect of PTL on the

and hsa-miR-483-5p for whole plasma and EV-depleted plasma. The

spectrum of circulating RNA and how they may be used as biomark-

qPCR and sequence results are in agreement, except hsa-miR-181c-5p

ers for PTB. As we do not have earlier samples from the individuals

in whole plasma and hsa-miR-377-3p in EV-depleted plasma (Fig-

we analysed, the study was limited to the characterization of circu-

ure 4). These discrepancies between NGS and qPCR results may be

lating RNA profiles from women already symptomatic for PTL. It is

due to low miRNA concentration or high sequence similarity with

possible that the labour itself affects the spectrum of circulating

other family members. Nevertheless, our interplatform agreement is

RNA; therefore, we need to be careful when interpreting the results.

higher than previously reported expectations.44

One of the biggest challenges for circulating miRNA analysis is
the inconsistency and irreproducibility of miRNA measurement
results which we also see in the PTL literature. There are a number

4 | DISCUSSION

of reasons for this problem including sample preparation method
and storage condition difference, low RNA concentration in the sam-

For this study, we overcame several challenges associated with the

ple and measurement platform difference.47 For this study, we

profiling and analysis of extracellular miRNA and identified several

adapted several newly developed or improved methods with
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results, the miRNA distribution between in and outside of EVs is
different and more miRNAs are located outside of EVs (in EVdepleted plasma; Table S3). There are at least four different
reported methods for cells to sort miRNAs into EVs, especially for
exosomes. These include protein-mediated processes—one by neural sphingomyelinase 2 (nSMase2)

49

and the other by AGO2

and sequence-dependent processes—uridine at 30 end

51

50

or a

sequence motif (GGAG) recognized by sumoylated heterogeneous
nuclear ribonucleoproteins (hnRNPs).52 It is unclear whether the
two protein-mediated processes, nSMase 2 and AGO2 mediated
miRNA sorting, are based on specific sequence motif(s). Examining
the miRNA sequences between EV and EV-depleted fractions, we
could not find any common sequence motif(s) including the known
exosomal miRNA-associated motif GGAG.52 It is difficult for us to
examine the non-template addition of nucleotide(s) at the 30 end
due to the 4N adapter used in library preparation; however, the
miRNAs showing higher concentrations in EVs have a higher per
cent of U at the 30 end compared to the EV-depleted fraction
(52% vs. 37%) (Figure S4A). In addition, the overall nucleotide composition of miRNAs preferentially packaged in EVs has a higher
percentage of U while sequences outside of EVs have a higher percentage of G (Figure S4B). These findings suggest that some miRNAs showed higher concentrations in EVs, and these miRNAs are
preferentially packaged into EVs by processes yet to be fully
F I G U R E 3 Volcano plots of miRNAs located in chromosome 14
(C14MC) (A) and chromosome 19 (C19MC) (B). The miRNA in whole
plasma is indicated in blue dots, EV in red dots and EV-depleted
plasma in yellow dots

determined.

expectations to gain a more accurate and comprehensive profile of

Placenta-associated mRNAs such as CSH1 (placental lactogen),

extracellular RNA. These methods include a new small RNA library

CGB1 (chorionic gonadotropin beta 1) and PLAC1 (placenta-speci-

construction protocol, a size exclusion chromatography (SEC)-based

fic protein 1), have been detected in maternal plasma, and their

EV purification method and a revised small RNA data analysis pipe-

concentration changes in plasma can be used to reflect the health

line.48 One of the advantages for SEC-based EV purification is the

of the placenta.53-55 In this study, we did not detect sufficient

ability to analyse RNA in both EV and EV-depleted fractions which

reads mapped to various placenta-enriched transcripts in either

allows the determination of RNA partition between the two com-

whole plasma, EV or EV-depleted plasma. This is probably due to

partments. With these improvements, we observed, on average,

our library size selection step which focuses on RNA molecules

more than 1,300 different miRNAs in the whole-plasma samples,

that are around 20 nucleotides in length. A library with a larger

1,100 miRNAs in the EV-depleted plasma and about 1,000 different

insert size may reveal more reads that map to protein-coding

miRNAs in the EV fraction. Our study also demonstrates results from

transcripts.

4.2 | Circulating RNA may reflect the condition of
placenta

this improved miRNA profiling approach provide better agreement

Nearly 50% of all PTL-affected miRNAs, especially in the EV

with results from qPCR: 12 of the 14 miRNAs measured with qPCR

fraction, identified in the study belong to two large imprinted miRNA

aligned with our NGS results (Figure 4). The two that did not might

clusters, C19MC and C14MC that are known to be expressed by the

be due to low miRNA concentration or high sequence similarity with

placenta suggesting that circulating miRNA profile is a relevant

other family members. The agreement between two different plat-

resource to reflect the condition of placenta. The miRNAs from the

forms further strengthens the small RNAseq findings and down-

C19MC region are expressed through the paternal allele and almost

stream analyses, such as network analysis.

exclusively by the placenta. They have been shown to play an important role in placenta development through regulating cell prolifera-

4.1 | Some miRNAs are enriched in EVs

tion, invasion and differentiation.20 The transcripts in the C14MC
region are expressed through the maternal allele,40 are usually acti-

Profiling both EV and EV-depleted plasma allowed us to unequivo-

vated at critical developmental stages and are involved in controlling

cally determine the partition of specific miRNA between in and

cell differentiation and fate in embryonic growth or placenta tis-

outside of EV in body fluid samples. Based on our sequencing

sues.56 Although most of the miRNAs in the C14MC cluster are not
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T A B L E 2 List of DEmiRNAs
Whole plasma

miRNA ID

C14MC

C19CM

EV

Fold change (log2)
PTL/control

P-value

0.86

1.76E02

hsa-miR-100-5p
hsa-miR-1-1-3p
hsa-miR-1179-5p
hsa-miR-1185-1-3p

X

0.83

3.94E06

0.82

3.02E03

hsa-miR-1185-1-5p

X

0.95

1.76E04

hsa-miR-1185-2-3p

X

0.72

2.29E03

hsa-miR-1246-5p

2.10

3.90E07

hsa-miR-1249-3p

1.23

3.81E04

hsa-miR-1256-3p

0.61

4.34E03

hsa-miR-126-3p

0.63

1.09E03

hsa-miR-126-5p
hsa-miR-127-3p

X

hsa-miR-127-5p

X

0.62

5.66E04

0.97

1.53E03

0.75

1.16E02

hsa-miR-1277-3p

1.42

5.46E09

hsa-miR-1277-5p

1.20

3.42E06

hsa-miR-130a-3p

0.69

2.10E03

hsa-miR-130a-5p

0.62

1.15E03

hsa-miR-1343-3p

0.68

4.79E03

hsa-miR-135a-1-5p

1.06

7.26E06

hsa-miR-136-3p

X

0.68

2.40E02

hsa-miR-136-5p

X

0.84

6.39E03

0.65

1.94E03

hsa-miR-146b-5p

0.69

8.22E05

hsa-miR-153-1-3p

0.61

5.55E04

0.75

3.77E03

hsa-miR-154-3p

X

hsa-miR-154-5p

X

hsa-miR-155-5p

Fold change (log2)
PTL/control

P-value

0.82

4.63E02

0.94

1.91E02

0.83

1.66E02

0.81

hsa-miR-141-3p
hsa-miR-142-3p

0.69

7.13E03

0.69

6.57E04

hsa-miR-181b-2-5p

0.61

4.16E04

hsa-miR-181c-3p

0.66

3.01E03

hsa-miR-181c-5p

0.96

1.63E06

hsa-miR-181d-5p

0.77

1.98E04

hsa-miR-183-5p

0.63

1.69E03

hsa-miR-186-3p

0.84

3.06E04

hsa-miR-193a-5p

0.96

9.50E05

hsa-miR-193b-3p

0.70

1.60E02

hsa-miR-192-5p

hsa-miR-194-1-5p
hsa-miR-199a-1-5p

0.89

7.18E05

hsa-miR-19b-2-3p

0.72

2.15E05

hsa-miR-20a-3p

0.85

6.27E06

hsa-miR-215-5p

0.79

2.07E02

hsa-miR-219a-1-5p

0.84

1.37E05

hsa-miR-214-3p

EV-depleted plasma
Fold change
(log2) PTL/control

P-value

1.04

3.46E02

1.14

5.38E03

0.92

4.46E02

7.49E03

0.71

2.26E02

0.63

3.55E02

0.69

4.40E02
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(Continued)
Whole plasma

miRNA ID

C14MC

C19CM

Fold change (log2)
PTL/control

EV
P-value

hsa-miR-221-3p

0.61

6.16E04

hsa-miR-26a-1-5p

0.76

1.17E04

hsa-miR-26a-2-3p

0.60

2.91E04

hsa-miR-26b-5p

0.80

9.30E06

hsa-miR-299-3p

X

0.64

2.17E02

hsa-miR-299-5p

X

0.81

2.25E03

hsa-miR-29a-5p

0.62

4.49E04

hsa-miR-29b-2-3p

1.11

2.93E07

hsa-miR-301a-3p

0.87

3.85E07

hsa-miR-301b-3p

0.85

2.64E05

hsa-miR-30d-3p

0.61

5.87E03

hsa-miR-32-3p

0.75

8.85E05

hsa-miR-324-5p

0.62

1.07E03

hsa-miR-328-3p

0.77

1.29E03

hsa-miR-331-3p

0.74

1.09E03

hsa-miR-335-3p
hsa-miR-337-3p

X

hsa-miR-337-5p

X

P-value

0.82

4.57E04

0.71

1.83E02

0.83

1.91E02

0.87

4.76E03

0.69

2.41E02

0.80

5.37E04

hsa-miR-33a-5p

0.67

1.52E02

hsa-miR-340-5p

0.75

1.07E04

hsa-miR-338-3p

Fold change (log2)
PTL/control

EV-depleted plasma

0.67

hsa-miR-33a-3p

hsa-miR-3611-3p

0.73

1.13E03

hsa-miR-3617-5p

0.85

1.32E04

hsa-miR-365a-3p

0.60

6.57E03

hsa-miR-3667-5p

0.67

2.29E02

hsa-miR-369-3p

X

0.68

1.90E02

0.96

7.59E03

X

0.63

2.48E02

0.90

2.78E02

hsa-miR-370-3p

0.81

8.12E03

0.93

2.39E06

hsa-miR-374b-3p

0.79

9.37E05

hsa-miR-374b-5p

0.79

4.16E05
8.44E03

hsa-miR-376a-1-3p

X

0.70

hsa-miR-376a-1-5p

X

0.90

2.51E04

hsa-miR-376b-3p

X

1.01

1.19E03

0.71

2.75E02

0.80

1.85E02

0.89

5.77E03

0.70

8.26E04

hsa-miR-376c-3p

X

0.66

2.17E02

hsa-miR-376c-5p

X

1.32

1.58E03

hsa-miR-377-3p

X

0.82

1.26E02

hsa-miR-378c-5p
hsa-miR-379-3p

X

0.80

4.61E03

0.83

4.30E02

hsa-miR-379-5p

X

0.73

2.04E02

0.82

3.12E02

1.08

3.48E03

0.80

3.11E02

hsa-miR-380-3p

X

0.66

1.45E02

hsa-miR-381-3p

X

0.72

9.41E03

hsa-miR-382-3p

X

P-value

0.82

1.79E02

0.86

4.24E02

1.19

1.46E02

2.14E02

hsa-miR-369-5p

hsa-miR-374a-5p

Fold change
(log2) PTL/control
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(Continued)
Whole plasma

miRNA ID

C14MC

hsa-miR-409-5p

X

hsa-miR-410-3p

X

C19CM

EV

Fold change (log2)
PTL/control

P-value

0.81

2.53E03

hsa-miR-411-3p

X

0.72

1.34E02

hsa-miR-411-5p

X

0.64

1.86E02

0.61

3.33E03

X

0.63

1.04E02

hsa-miR-421-5p
hsa-miR-431-3p
hsa-miR-431-5p

X

0.67

3.01E02

hsa-miR-432-3p

X

0.68

4.51E03

hsa-miR-4326-5p
hsa-miR-450a-1-5p
hsa-miR-4532-5p
hsa-miR-454-3p
hsa-miR-4732-5p
hsa-miR-483-5p

0.61

4.93E03

0.84

4.07E02

0.64

9.36E05

0.76

1.15E05

1.18

5.55E04

X

0.66

1.90E02

0.75

9.07E06

X

0.77

6.01E03

hsa-miR-487b-3p

X

0.68

1.38E02

hsa-miR-487b-5p

X

hsa-miR-485-3p
hsa-miR-486-1-5p
hsa-miR-487a-3p

0.74

8.20E04

hsa-miR-493-3p

X

0.74

1.01E02

hsa-miR-493-5p

X

0.72

1.08E02

hsa-miR-491-5p

hsa-miR-494-3p

X

0.76

7.83E03

hsa-miR-495-3p

X

0.75

8.20E03

hsa-miR-495-5p

X

0.64

9.50E03

hsa-miR-505-5p

EV-depleted plasma

Fold change (log2)
PTL/control

P-value

0.77

1.54E02

0.84

3.90E02

0.70

4.89E02

0.66

1.01E02

0.67

0.67

4.24E02

0.61

1.36E02

hsa-miR-512-1-5p

X

0.85

4.14E02

X

0.82

2.35E02

hsa-miR-515-1-5p

X

0.97

2.45E02

hsa-miR-516b-1-5p

X

0.91

3.62E02

hsa-miR-517a-3p

X

0.96

1.90E02

hsa-miR-517c-3p

X

1.04

1.92E02

hsa-miR-518b-3p

X

1.19

1.50E02

hsa-miR-518c-3p

X

1.03

4.42E02

hsa-miR-518f-3p

X

0.94

2.25E02

hsa-miR-518f-5p

X

0.95

3.93E02

hsa-miR-519d-3p

X

hsa-miR-520a-3p

X

1.39

1.15E03

0.64

2.46E03

0.66

1.61E02

hsa-miR-520d-5p

X

1.01

8.36E03

hsa-miR-524-5p

X

0.94

4.56E02

hsa-miR-525-5p

X

1.26

1.22E02

hsa-miR-526b-5p

X

0.79

4.88E02

0.92

1.22E02

hsa-miR-539-3p

X

0.84

3.66E03

P-value

1.33

1.08E02

0.63

3.05E02

0.83

2.40E02

4.82E02

hsa-miR-515-1-3p

hsa-miR-5193-3p

Fold change
(log2) PTL/control
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(Continued)
Whole plasma

miRNA ID

C14MC

C19CM

Fold change (log2)
PTL/control

EV
P-value

hsa-miR-545-5p

0.79

2.36E05

hsa-miR-548a-1-3p

0.76

8.36E03

hsa-miR-548a-3-5p

0.71

2.35E03

hsa-miR-548ax-3p

0.68

1.47E03

hsa-miR-548ax-5p

0.79

7.02E04

hsa-miR-551b-3p

0.71

2.24E03

hsa-miR-556-3p

0.73

6.56E04

hsa-miR-556-5p

0.85

4.70E04

hsa-miR-582-5p

0.61

2.23E02

1.25

6.34E07

hsa-miR-589-3p
hsa-miR-590-3p
hsa-miR-590-5p

0.76

4.93E05

hsa-miR-625-5p

0.61

2.70E03

hsa-miR-627-3p

0.63

3.78E03

hsa-miR-628-5p

0.75

2.27E06

0.67

1.47E03

X

0.63

3.71E02

hsa-miR-655-3p

X

0.69

1.30E02

hsa-miR-656-3p

X

hsa-miR-6516-5p
hsa-miR-654-3p

hsa-miR-664a-3p

0.66

5.82E05

hsa-miR-671-5p

0.64

2.55E03

hsa-miR-6741-3p

0.62

1.52E03

hsa-miR-744-3p
hsa-miR-758-3p

X

0.65

1.24E03

0.91

4.00E03

0.62

1.14E02

0.60

2.98E02

hsa-mir-7641-2
hsa-miR-877-3p
hsa-miR-889-3p

X

hsa-miR-92a-2-3p
0.60

hsa-miR-99b-3p

EV-depleted plasma

Fold change (log2)
PTL/control

P-value

0.74

1.45E02

0.71

2.26E03

0.68

2.98E02

0.91

8.58E03

1.01

4.12E03

0.74

1.23E02

0.65

6.42E03

0.68

3.14E02

0.73

9.10E03

Fold change
(log2) PTL/control

P-value

1.25E02

Of the 668 detectable miRNAs in whole plasma (631 shared plus 20 in control and 17 in PTL), 132 showed a significant concentration difference
(≥1.5 change and P-value ≤.05) between the preterm and normal gestation groups. Likewise, 51 of the 535 detectable miRNAs in EVs (476 shared
plus 36 in control and 23 in PTL) had significant concentration changes between the preterm and normal gestation groups. Only 10 of the 585
detectable miRNA in the EV-depleted plasma samples (486 shared plus 98 in control and 1 in PTL) had significant concentration changes between
the two groups.

exclusively expressed in the placenta, an analysis of healthy human

the concentration changes of those miRNAs are different from the

tissues showed that some members of C14MC, for example hsa-

current report. Like what we observed in liver toxicity,63 there is a

miR-381,

predominantly

reverse correlation on concentration changes between plasma and

and the concentrations of all three miR-

tissue. For example, the level of hsa-miR-483-5p is lower in placen-

hsa-miR-154

expressed in the placenta

and
57

hsa-miR-377,

are

NAs are significantly decreased in PTL samples in our study.

tas from PTL compared to full-term pregnancies whereas we show

In fact, most of the affected miRNAs identified in this study

an increased concentration in plasma of patients with PTL.45,46 The

showed decreased concentrations in PTL samples (whole plasma, EV

levels of hsa-miR-154-5p, hsa-miR-135a-5p, hsa-miR-142-3p, hsa-

or EV-depleted plasma). Some of these miRNAs have been reported

miR-136-5p, hsa-miR-517a, hsa-miR-518b and hsa-miR-526b were

to be associated with pregnancy-related conditions. For example the

increased in the placenta tissues of patients with PTL

plasma hsa-miR-517a level has been associated with ectopic preg-

our data show a significant reduction in these miRNAs in circulation

nancy and preeclampsia,58,59 and the plasma levels of several of the

in patients with PTL. The reverse correlation of miRNA concentra-

hsa-miR-520s in preeclampsia and molar pregnancy.60-62 However,

tion changes between tissue and circulating miRNA has been

64

whereas
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4.3 | Key processes in placenta may be influenced
by dysregulated miRNAs in PTL
From the PTL-affected miRNAs identified from whole plasma, EVs
and EV-depleted plasma, we conducted analysis to determine the
perturbed networks represented by these dysregulated miRNAs in
PTL. Based on TargetScan and miRTar databases,31,32 the 127 differentially expressed miRNAs in PTL patient samples may interact with
more than 11 000 different genes. To better reflect the changes of
biological processes in placenta, we focused on the 70 miRNAs and
354 mRNAs that are enriched in placenta.33 We further expanded
the 354 placenta-enriched proteins with its first neighbour using
F I G U R E 4 Validation of small RNA sequencing results. Some of
the affected miRNAs determined by sequencing (open bars) were
validated by qPCR (solid bars). The X-axis indicates the identity of
affected miRNA, and the Y-axis is the fold changes in either cycle
number (qPCR) or log2 transformed reads per million (RPM) adjusted
read counts (small RNAseq)

protein-protein interaction information,34-36 which allowed us to gain
a more complete picture of the affected network. This produced a
total of 3858 miRNA-mRNA interactions between 70 miRNAs and
1,341 mRNAs. The 1341 protein-coding mRNAs are mainly associated with processes involving signalling transduction and cell-extracellular matrix interactions which are important processes involved
in placenta and foetal development (Table 3). To illustrate the com-

reported, for example in a drug-induced liver injury, the miR-122

plexity of miRNA-mRNA interactions, Figure 5 shows a detailed

level is decreased in liver tissue but showed a significant increase

miRNA-mRNA interaction network based on 4 cell proliferation-

in plasma. The increase in miR-122 concentration in plasma proba-

related pathways: PI3K AKT signalling, VEGF signalling, focal adhe-

bly is caused by miRNA released during hepatocyte death. In the

sion and gap junction pathways derived from EV-affected miRNA.

case of PTL, we are not sure what caused the concentration differ-

The network contains 401 interactions between 54 miRNAs and

ence between placenta and plasma. The dysfunction of placenta

108 mRNAs. A number of miRNAs in the C14MC and C19MC

during PTL probably affects the release of miRNA into the

regions are targeting key regulators. For example, TP53 is targeted

extracellular environment. Further study is needed to resolve this

by hsa-miR-379-5p (from C14MC), MYC is targeted by hsa-miR-

discrepancy.

487b-3p and hsa-miR-494-3p (from C14MC), MET is targeted by

T A B L E 3 List of putative circulating miRNA interacted pathways in placenta
KEGG ID

Pathway description

Plasma

EV

Depleted

hsa04510

Focal adhesion

5.81E15

6.35E13

7.79E04

hsa04012

ErbB signalling pathway

3.44E12

1.24E13

3.49E03

hsa04520

Adherens junction

1.12E11

1.37E13

1.07E03

hsa04110

Cell cycle

2.05E11

2.53E11

2.25E02

hsa04917

Prolactin signalling pathway

7.10E11

2.53E09

2.22E02

hsa04151

PI3K-Akt signalling pathway

1.01E10

2.57E10

7.82E04

hsa04144

Endocytosis

4.92E10

2.41E09

7.03E05

hsa04540

Gap junction

3.70E09

1.34E05

hsa04350

TGF-beta signalling pathway

5.50E09

1.56E08

1.79E05

hsa04666

Fc gamma R-mediated phagocytosis

1.13E07

1.56E08

5.99E04

hsa04071

Sphingolipid signalling pathway

1.49E06

4.17E06

1.56E03

hsa04664

Fc epsilon RI signalling pathway

2.60E06

2.07E05

hsa04370

VEGF signalling pathway

1.21E04

2.13E05

hsa04010

MAPK signalling pathway

2.27E04

3.80E04

6.45E02

hsa04530

Tight junction

9.45E04

3.28E04

3.86E03

hsa04512

ECM-receptor interaction

2.84E03

hsa04068

FoxO signalling pathway

5.16E08

4.43E09

1.11E02

hsa04152

AMPK signalling pathway

2.19E03

5.64E06

5.88E02

hsa04914

Progesterone-mediated oocyte maturation

6.89E03

1.37E03
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F I G U R E 5 Schematic diagram of perturbed gene network in placenta that may be reflected by the changes of circulating miRNAs in PTL.
The network is built based on the KEGG pathway maps: focal adhesion (hsa04510), PI3K-Akt signalling pathway (hsa04151), gap junction
(hsa04540) and VEGF signalling pathway (hsa04370) which were from results of the enrichment analysis of miRNA targets. The genes are
indicated by circles and miRNAs by diamonds. The predicted miRNA-mRNA interactions are indicated by light grey lines, and the blue lines are
validated miRNA-mRNA interactions. The identity of genes and miRNAs involved in the process are indicated, and the red colour indicates
placenta-enriched mRNAs and miRNAs
hsa-miR-369-3p and hsa-miR-410-3p (from C14MC), and PTEN by

colocalized with a large cluster of SnoRNAs. One of them, the

hsa-miR-519d-3p,

SNORD114 promotes cell cycle progression and overexpressing

hsa-miR-520d-3p

and

hsa-miR-524-5p

(from

C19MC; Figure 5).

SNORD114 induces K562 and HCT116 cell proliferation. Even
though we do not know their function, these PTL-affected non-cod-

4.4 | PTL may also affect the spectrum of other
RNAs in circulation

ing RNAs identified in this study may lead to future functional studies on their involvement in normal foetal development.
In conclusion, we provide evidence for an altered profile of circu-

Besides miRNA, our pipeline also reports other types of RNA in cir-

lating RNA including miRNA and other small RNAs in the plasma

culation. Like miRNA, we observed that the concentration of other

from women with PTLs as compared to normal pregnancies and con-

RNAs including small nucleolar RNA (SnoRNA), piwi-interacting RNA

firm the levels of some differentially expressed miRNAs (DEmiRNAs)

(piRNA) and long non-coding RNA (lncRNA) was affected in patients

in the whole plasma, EVs and EV-depleted plasma by real-time

with PTL (Table S4). The two affected SnoRNAs: SNORD22 and

qPCR. We show that some of the EVs in plasma from pregnant

SNORD26 are encoded by small nucleolar RNA host gene 1

women most likely originate from the placenta and make EV-asso-

(SNHG1) on chromosome 11, and both of their concentrations

ciated molecules a useful and relatively non-invasive source of

increased in PTL plasma samples. Unlike miRNA, we know very little

biomarkers for PTL. Further investigation with longitudinal and larger

about the function of these RNAs; however, they probably also par-

number of samples is required to validate a specific EV-associated

ticipate in foetal development. For example, the C14MC cluster is

miRNA panel that can be used towards this goal.
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